The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Role of Cytochrome P4502B6 Polymorphisms in Ketamine Metabolism and Clearance
Abstract
Background: At therapeutic concentrations, cytochrome P4502B6 (CYP2B6) is the major P450 isoform catalyzing hepatic ketamine N-demethylation to norketamine in vitro. The CYP2B6 gene is highly polymorphic. The most common variant allele, CYP2B6*6, is associated with diminished hepatic CYP2B6 expression and catalytic activity compared with wild-type CYP2B6*1/*1. CYP2B6.6, the protein encoded by the CYP2B6*6 allele, and liver microsomes from CYP2B6*6 carriers had diminished ketamine metabolism in vitro. This investigation tested whether humans with the CYP2B6*6 allele would have decreased clinical ketamine metabolism and clearance. Methods: Thirty volunteers with CYP2B6*1/*1, *1/*6, or *6/*6 genotypes (n = 10 each) received a subsedating dose of oral ketamine. Plasma and urine concentrations of ketamine and the major CYP2B6-dependent metabolites were determined by mass spectrometry. Subjects’ self-assessment of ketamine effects were also recorded. The primary outcome was ketamine N-demethylation, measured as the plasma norketamine/ketamine area under the curve ratio. Secondary outcomes included plasma ketamine enantiomer and metabolite area under the plasma concentration–time curve, maximum concentrations, apparent oral clearance, and metabolite formation clearances. Results: There was no significant difference between CYP2B6 genotypes in ketamine metabolism or any of the secondary outcome measures. Subjective self-assessment did reveal some differences in energy and level of awareness among subjects. Conclusions: These results show that while the CYP2B6*6 polymorphism results in diminished ketamine metabolism in vitro, this allelic variant did not affect single, low-dose ketamine metabolism, clearance, and pharmacokinetics in vivo. While in vitro drug metabolism studies may be informative, clinical investigations in general are needed to validate in vitro observations.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Ketamine is metabolized within minutes after administration by nitrogen-mediated demethylation to norketamine, mediated primarily by cytochrome P450 liver enzymes [18,19].”
From Ketamine in neuropsychiatric disorders: an update (2024) · cites this paper as [19]
Citations
Cites
A physiological approach to hepatic drug clearance
Wilkinson, G. R., & Shand, D. G. (1975) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1975184377 · Cited by 1,873
THE HUMAN INTESTINAL CYTOCHROME P450 “PIE”
Paine, M. F., Hart, H. L., Ludington, S. S., Haining, R. L., Rettie, A. E., & Zeldin, D. C. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.008672 · Cited by 870
Murrough, J. W., Perez, A. M., Pillemer, S., Stern, J., Parides, M. K., aan het Rot, M., Collins, K. A., Mathew, S. J., Charney, D. S., & Iosifescu, D. V. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.06.022 · Cited by 786
Morgan, E. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.302 · Cited by 462
PHARMACOKINETICS AND ANALGESIC EFFECTS OF I.M. AND ORAL KETAMINE
GRANT, I. S., NIMMO, W. S., & CLEMENTS, J. A. (1981) · British Journal of Anaesthesia · doi:10.1093/bja/53.8.805 · Cited by 355
Zanger, U. M., & Klein, K. (2013) · Frontiers in Genetics · doi:10.3389/fgene.2013.00024 · Cited by 345
Hijazi, Y., & Boulieu, R. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.7.853 · Cited by 287
HCN1 Channel Subunits Are a Molecular Substrate for Hypnotic Actions of Ketamine
Chen, X., Shu, S., & Bayliss, D. A. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.3481-08.2009 · Cited by 277
KHARASCH, E., HOFFER, C., WHITTINGTON, D., & SHEFFELS, P. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.05.003 · Cited by 238
Self-citationInvolvement of CYP2B6 in n-demethylation of ketamine in human liver microsomes.
Yanagihara, Y., Kariya, S., Ohtani, M., Uchino, K., Aoyama, T., Yamamura, Y., & Iga, T. (2001) · PubMed · Cited by 209
Research works printed but not linked: 1
- 1990, Biotransformation of ketamine, Status of Ketamine in Anesthesiology, 93
Cited by
Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms
Zanos, P., Moaddel, R., Morris, P. J., Riggs, L. M., Highland, J. N., Georgiou, P., Pereira, E. F. R., Albuquerque, E. X., Thomas, C. J., Zarate, C. A., et al. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.015198 · Cited by 1,260
Schwenk, E. S., Viscusi, E. R., Buvanendran, A., Hurley, R. W., Wasan, A. D., Narouze, S., Bhatia, A., Davis, F. N., Hooten, W. M., & Cohen, S. P. (2018) · Regional Anesthesia and Pain Medicine · doi:10.1097/aap.0000000000000806 · Cited by 584
Cohen, S. P., Bhatia, A., Buvanendran, A., Schwenk, E. S., Wasan, A. D., Hurley, R. W., Viscusi, E. R., Narouze, S., Davis, F. N., Ritchie, E. C., et al. (2018) · Regional Anesthesia and Pain Medicine · doi:10.1097/aap.0000000000000808 · Cited by 350
“4 mg/kg) oral administration.(92) Thus, the effects of these polymorphisms in studies evaluating higher, IV dosages remains unknown.”
The antidepressant actions of ketamine and its enantiomers
Johnston, J. N., Henter, I. D., & Zarate, C. A. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108431 · Cited by 118
Expanding Role of NMDA Receptor Antagonists in the Management of Pain
Kreutzwiser, D., & Tawfic, Q. A. (2019) · CNS Drugs · doi:10.1007/s40263-019-00618-2 · Cited by 114
Metadata
- Authors
- Rao, L. K., Flaker, A. M., Friedel, C. C., & Kharasch, E. D.
- Affiliations
- Washington University in St. Louis (US)
- Corresponding author
- Rao, Lesley K.
- ORCID
- Kharasch, Evan D.
- Venue
- Anesthesiology
- Published
- 2016-12-01
- Volume
- 125
- Issue
- 6
- Pages
- 1103-1112
- ISSN
- 0003-3022 (ISSN-L)
- OpenAlex
- W2536089988
- Cited by
- 67
- References
- 34
- Citations by year
- 2026: 5 · 2025: 7 · 2024: 5 · 2023: 5 · 2022: 10 · 2021: 11 · 2020: 9 · 2019: 3 · 2018: 10 · 2017: 1 · 2016: 1
- FWCI
- 6.29
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Anesthesiology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Drug Abuse (R01DA014211)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Anesthesia and Sedative Agents
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Keywords
- ketamine, CYP2B6, norketamine, pharmacokinetics, drug metabolism polymorphisms, ketamine enantiomers, ketamine metabolites
- MeSH terms
- Adolescent, Adult, Anesthetics, Dissociative, Female, Humans, Ketamine, Male, Middle Aged, Polymorphism, Genetic, Young Adult, Cytochrome P-450 CYP2B6
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Role of Cytochrome P4502B6 Polymorphisms in Ketamine Metabolism and Clearance. https://app.cochat.ai/papers/10.1097/aln.0000000000001392
- The paper
- Rao, L. K., Flaker, A. M., Friedel, C. C., & Kharasch, E. D. (2016). Role of Cytochrome P4502B6 Polymorphisms in Ketamine Metabolism and Clearance. Anesthesiology. https://doi.org/10.1097/aln.0000000000001392
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.